Daniel Barenboim, Parkinson's disease
The study may suggest that other researchers should be less optimistic about the prospects for treating a range of other ...
The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.
Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite earlier evidence from a phase 2 ...
The glucagon-like peptide-1 receptor agonist exenatide does not yield improvement in measures of Parkinson disease seve ...
The FDA approved an apomorphine hydrochloride infusion device (Onapgo) to treat motor fluctuations in adults with advanced ...
Sharon Osbourne, his wife, told The Sun her husband’s voice is still up to the task of performing.
Onapgo is a subcutaneous apomorphine infusion device for the treatment of motor fluctuations in patients with advanced disease ...
AI-powered blood test detects Parkinson's disease years before symptoms appear, revolutionizing early diagnosis and treatment ...
The Google cofounder has donated more than $1.5 billion to Parkinson’s research. Now, as he takes on autism, he’s also ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback